T-Cell Lymphoma News

Expert Shares Insight on Developments in T-Cell Lymphoma - OncLive



OncLive
 
Expert Shares Insight on Developments in T-Cell Lymphoma 
OncLive
OncLive: Can you provide an overview of your presentation on T-cell lymphoma? Brammer: T-cell lymphomas have been an area of limited progress and poor overall prognosis. Over the past several years, we've had some exciting new developments. One of ...

 


FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma - FDA.gov



Curetoday.com
 
FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma 
FDA.gov
The U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two ...
CAR T-Cell Therapy Yescarta Approved to Treat Non-Hodgkin Lymphoma Curetoday.com
FDA Approves Yescarta, First CAR T-Cell Therapy for Lymphoma Managed Care magazine
CAR T-Cell Approvals Leading Landscape of Hematologic Cancers OncLive
Markets Insider  -gilead.com 
all 205 news articles » 


Darby rallies around grad diagnosed with lymphoma - Ravalli Republic



Ravalli Republic
 
Darby rallies around grad diagnosed with lymphoma 
Ravalli Republic
Darby Jake Sanders. Buy Now. Jake ?Sunshine? Sanders, 19, is a recent Darby graduate who was diagnosed with non-Hodgkin T-cell Lymphoma two months ago. The Darby community is coming together to raise money to help cover his medical expenses.

 


Peripheral T-cell lymphoma linked to textured breast implants - Drug Target Review (press release)



Drug Target Review (press release)
 
Peripheral T-cell lymphoma linked to textured breast implants 
Drug Target Review (press release)
Breast implant-associated anaplastic large cell lymphoma ? or BIA-ALCL ? is a rare peripheral T-cell lymphoma that may develop in patients with breast implants. The researchers at Penn State College of Medicine have said the cancer is likely ...
Rare cancer linked with textured breast implants may be ... Science Daily

all 5 news articles » 


FDA approves 2nd gene therapy targeting non-Hodgkin lymphomas - East Idaho News



East Idaho News
 
FDA approves 2nd gene therapy targeting non-Hodgkin lymphomas 
East Idaho News
The new drug is made by California-based Kite, a subsidiary of drug giant Gilead Sciences that develops chimeric antigen receptor and T-cell receptor (CAR-T) cell therapies. These new treatments use a patient's own T-cells to seek and destroy cancer cells.
FDA approves Gilead cancer gene therapy; price set at $373,000 Reuters
FDA Approves Second CAR-T Therapy In US To Gilead's Kite Pharma Pharmaceutical Online (press release)
Gilead (GILD) CAR-T Therapy Yescarta Clinches FDA Approval ... Zacks.com
Philadelphia Business Journal  -DeathRattleSports.com 
all 10 news articles » 


FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma - OncLive



FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma 
OncLive
The FDA has approved the CD19-directed CAR T-cell therapy axicabtagene ciloleucel as a treatment for adults with relapsed or refractory non-Hodgkin ...
FDA Approves Axi-Cel for Large B-cell Lymphoma Targeted Oncology

all 2 news articles » 


Cancer linked with breast implants 'may be underreported' - International Federation of Gynecology and Obstetrics



Cancer linked with breast implants 'may be underreported' 
International Federation of Gynecology and Obstetrics
Dr Ravnic said that all manufacturers of textured implants have seen cases linked to this type of lymphoma, while there have been no cases linked to smooth implants. He went on to add: ?But in many of these cases the implant was removed without testing ...

 


Published Case Study? A report of three cases of NK/T-Cell Lymphoma enrolled in the prospective Kamuzu Central ... - Lymphoma Hub



Lymphoma Hub
 
Published Case Study? A report of three cases of NK/T-Cell Lymphoma enrolled in the prospective Kamuzu Central ... 
Lymphoma Hub
... to radiotherapy and chemotherapy limitations, patients were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) with rapid disease progression. All three patients died from progressive lymphoma within 3 months of initial ...

 


Next-gen CAR-T firm Autolus takes funding tally to $173M ... - FierceBiotech



FierceBiotech
 
Next-gen CAR-T firm Autolus takes funding tally to $173M ... 
FierceBiotech
London-based CAR-T player Autolus has raised $80 million in a third-round financing that it says will fund proof-of-concept testing for three programs.
AUTOLUS LIMITED: Autolus Secures US$80 million Series C Funding GlobeNewswire (press release)

all 9 news articles » 


New CAR-T cell therapy offers effective option for certain blood cancer patients - News-Medical.net



fox6now.com
 
New CAR-T cell therapy offers effective option for certain blood cancer patients 
News-Medical.net
Newly approved by the Food and Drug Administration (FDA) for types of advanced non-Hodgkin lymphoma in adults, the CAR-T cell therapy harnesses a patient's own immune system to fight cancer. Washington University doctors and researchers were ...
FDA approves 2nd gene therapy targeting non-Hodgkin lymphomas ... fox6now.com
CAR-T immunotherapy may help blood cancer patients who don't ... Medical Xpress
FDA approves Kite's CAR-T cell therapy; another win for NCI's intramural program The Cancer Letter Publications
ModernMedicine  -Technology Networks  -Tampabay.com (blog) 
all 29 news articles »